Is It Time to Incorporate Liquid Biopsy into High-Risk Cancer Surveillance Protocols in Li-Fraumeni Syndrome?
Cancer Discov
; 14(1): 23-25, 2024 01 12.
Article
em En
| MEDLINE
| ID: mdl-38213298
ABSTRACT
SUMMARY:
In the first prospective study evaluating circulating tumor DNA (ctDNA) for early cancer detection, Wong, Luo, and colleauges demonstrate the feasibility of liquid biopsy as an augmentation to current surveillance protocols for patients with Li-Fraumeni syndrome, an inherited cancer predisposition associated with high cancer risk in both pediatric and adult populations. Though additional clinical validation in larger cohorts is needed, this research highlights that a multimodal approach is likely necessary to improve the sensitivity of liquid biopsy assays for early cancer detection. See related article by Wong, Lou et al., p. 104 (9).
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Síndrome de Li-Fraumeni
/
Ácidos Nucleicos Livres
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article